Details of the Drug Formulation (DFM)
| General Information of DFM (ID: F23717) | |||||
|---|---|---|---|---|---|
| Name |
Dinoprostone 10mg extended release insert
|
||||
| Company |
Ferring Pharmaceuticals
|
||||
| Active Pharmaceutical Ingredient (API) | Dinoprostone |
API Info
 click to show the detail info of this API
|
|||
| Approved | |||||
| Drug Inactive Ingredient (DIGs) | |||||
| DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
| E0G3NO | DIG Info | Polyethylene glycol 4000 | Coating agent ... | ||
| Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
|---|---|---|---|---|---|---|
| Oxidoreductase (ORase) | ||||||
| DBT Name: Albendazole monooxygenase (CYP3A4) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Polyethylene glycol 4000 | |||||
| Biological Activity | Inhibition ratio < 40 % (tested by experiment) | [1] | ||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | CP3A4_HUMAN | |||||
| References | |||||
|---|---|---|---|---|---|
| 1 | Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.